CEO William John Miller sold ~$10.8M in open-market sales over two days (Aug 13-17), and CFO John P. Kiernan sold $525K on Aug 10, forming a clear insider selling cluster totaling ~$11.4M. At a $3.1B market cap, this represents ~0.37%, a modest but notable amount, amplified by the CEO's dominant role and the cluster's concentration. The selling is not explained by 10b5-1 patterns or vesting, and the CEO's sales are large in absolute terms, suggesting potential caution ahead of near-term events. The cross-filing actuarial verdicts flag multiple amplifiers (cluster-insider-trades + cluster-press-context, etc.), but no press or earnings context is present in the provided documents, so these are not triggered. The cluster is treated on its standalone merits as a modest bearish signal from top executives, not a transformative event. Score is set at 5 (notable but not significant) given the proportionality and lack of amplifying context. Sentiment is bearish due to the CEO's material open-market sales without a clear liquidity rationale. Key facts: CEO sold ~$10.8M in open-market sales; CFO sold $525K; total cluster value ~$11.4M (0.37% of market cap); no 10b5-1 pattern evident; director gift of 3,000 shares is non-cash and neutral. Actionable insight: Monitor for any upcoming 8-K or press release that could explain the CEO's concentrated selling, if no news emerges within 2 weeks, the selling may be liquidity-driven and less informative. Related tickers: none. Time horizon: days to weeks. Data: netDirection 'selling', totalValue 11400000 (sum of CEO $10.8M + CFO $525K = $11.4M), insiderCount 2, cSuiteCount 2 (CEO and CFO), possibleCatalyst 'null'. Drug names: empty array (not biotech). Cross-filing narrative: no amplifying cross-filing context present, standalone cluster analysis. Confidence: medium (no 10b5-1 plan disclosure, no recent earnings or press release to contextualize).
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $47.20entry
- T+1 · 3mo ago +1.40%α +0.99% · $47.86
- T+5 · 3mo ago −0.53%α −1.64% · $46.95
- T+20 · 2mo ago −12.27%α −12.27% · $41.41
- T+60 · 4d ago −14.56%α −13.72% · $40.33
Price Chart
How similar events traded
Executive Summary
CEO William John Miller sold ~$10.8M in open-market sales over two days (Aug 13-17), and CFO John P. Kiernan sold $525K on Aug 10, forming a clear insider selling cluster totaling ~$11.4M. At a $3.1B market cap, this represents ~0.37%, a modest but notable amount, amplified by the CEO's dominant role and the cluster's concentration. The selling is not explained by 10b5-1 patterns or vesting, and the CEO's sales are large in absolute terms, suggesting potential caution ahead of near-term events. The cross-filing actuarial verdicts flag multiple amplifiers (cluster-insider-trades + cluster-press-context, etc.), but no press or earnings context is present in the provided documents, so these are not triggered. The cluster is treated on its standalone merits as a modest bearish signal from top executives, not a transformative event. Score is set at 5 (notable but not significant) given the proportionality and lack of amplifying context. Sentiment is bearish due to the CEO's material open-market sales without a clear liquidity rationale. Key facts: CEO sold ~$10.8M in open-market sales; CFO sold $525K; total cluster value ~$11.4M (0.37% of market cap); no 10b5-1 pattern evident; director gift of 3,000 shares is non-cash and neutral. Actionable insight: Monitor for any upcoming 8-K or press release that could explain the CEO's concentrated selling, if no news emerges within 2 weeks, the selling may be liquidity-driven and less informative. Related tickers: none. Time horizon: days to weeks. Data: netDirection 'selling', totalValue 11400000 (sum of CEO $10.8M + CFO $525K = $11.4M), insiderCount 2, cSuiteCount 2 (CEO and CFO), possibleCatalyst 'null'. Drug names: empty array (not biotech). Cross-filing narrative: no amplifying cross-filing context present, standalone cluster analysis. Confidence: medium (no 10b5-1 plan disclosure, no recent earnings or press release to contextualize).
Financial Impact
Not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VECO-1787173626263 |
Track record
17 reports on VECO
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +36.28% at T+60 after the Jun 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $39.60 Now $37.20 −6.06% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $33.25 Now $37.20 +11.88% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $33.25 Now $37.20 +11.88% settles Feb 3
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $37.27 Now $37.20 −0.19% settles Jan 29
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $42.80 Now $37.20 −13.08% settles Jan 27
- Aug 19, 202612w ago Insider Cluster Neutral Not scored Viewing Entry $47.20 to $40.33 Now $37.20 −21.19% ▼ −14.56% −13.72% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $71.55 to $45.59 Now $37.20 +48.01% ▲ +36.28% +40.10% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 4/10 Entry $71.55 to $45.59 Now $37.20 −48.01% ▼ −36.28% −40.10% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $71.55 to $45.59 Now $37.20 −48.01% ▼ −36.28% −40.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers